Process of production of a formulation comprising therapeutically active or nutritious plant extracts

Abstract

This invention relates to a process for producing solid formulations. These solid formulations comprise therapeutically active or nutritious plant extracts, which are known for being bad-tasting. These new solid formulation are neutral in taste. Furthermore the present invention relate to these solid formulations as well as to their use in the production of food, feed, nutritional supplement and personal care products.

Claims

1. A process for the production of a solid formulation comprising: (i) 20-40 weight-% (wt-%), based on the total weight of the solid formulation, of an Acerola plant extract, and (ii) 60-80 wt-%, based on the total weight of the solid formulation, of at least one lipophilic material, wherein the process comprises the steps of: (a) providing the lipophilic material in a molten state, (b) forming a suspension of the lipophilic material and the Acerola plant extract by suspending the Acerola plant extract in the molten lipophilic material, and thereafter (c) introducing the suspension into a spray tower comprising atomizing air, in which the atomizing air has a temperature that causes solidification of the liquid lipophilic material, thereby forming solid particles thereof containing the Acerola plant extract.

2. The process according to claim 1, wherein the lipophilic material is at least one wax and/or fat having a drop point of from 30 to 90 C.

3. The process according to claim 1, wherein the lipophilic material is at least one wax and/or fat selected from the group consisting of glycerol monostearate, carnauba wax, candelilla wax, palmitic acid, stearic acid hydrogenated cottonseed oil and hydrogenated rapeseed oil.

4. The process according to claim 1, wherein the lipophilic material is glycerol monostearate.

5. The process according to claim 1, wherein the suspension formed according to step (b) comprises 20-35 wt-%, based on the total weight of the solid formulation, of the Acerola plant extract.

6. The process according to claim 1, wherein the suspension formed according to step (b) comprises 65-80 wt-%, based on the total weight of the solid formulation, of the at least one lipophilic material.

7. The process according to claim 1, wherein the solid particles formed according to step (c) have an average particle size (d50) of between 40-500 m.

8. The process according to claim 1, wherein the solid formulation consists of: (i) 20-40 weight-% (wt-%), based on the total weight of the solid formulation, of the Acerola plant extract, and (ii) 60-80 wt-%, based on the total weight of the solid formulation, of glycerol monostearate as the lipophilic material.

9. The process according to claim 2, wherein the at least one wax and/or fat has a drop point of from 40 to 80 C.

Description

DETAILED DESCRIPTION

(1) The present invention is directed toward a solid formulation and a process (P) for the production of such solid formulation, wherein the solid formulation comprises: (i) 20-40, weight-% (wt-%), based on the total weight of the solid formulation, of least one therapeutically active or nutritious plant extract, and (ii) 60-80 wt-%, based on the total weight of the solid formulation, of at least one lipophilic material, characterized in that (a) at least one therapeutically active or nutritious plant extract is suspended in the at least one liquid lipophilic material, and (b) this suspension is atomized into a spray tower, wherein the air has such a temperature that the lipophilic material solidifies.

(2) The new and improved solid formulation has also the additional advantages that the solid formulation is easy to produce (conventional spray technology), the solid formulation has excellent properties to mask sour/bitter tastes, the solid formulation is a non-sticky powder, and the therapeutically active or nutritious plant extract is very well protected against moisture.

(3) The therapeutically active or nutritious plant extract is preferably an Acerola plant extract.

(4) In a preferred embodiment, the amount of this plant extract is 20-35 wt-%, based on the total weight of the solid formulation.

(5) Therefore, the present invention also relates to a process (P1), which is process (P), wherein the therapeutically active or nutritious plant extract is an Acerola plant extract.

(6) In a preferred embodiment, the amount of the therapeutically active or nutritious plant extract in the solid formulation is 20-35 wt-%, based on the total weight of the solid formulation.

(7) Therefore the present invention also relates to a process (P2), which is process (P) or (P1), wherein the amount of the therapeutically active or nutritious plant in the solid formulation is 20-35 wt-%, based on the total weight of the solid formulation.

(8) In a preferred embodiment, the amount of the lipophilic material in the solid formulation is 65-80 wt-%, based on the total weight of the solid formulation.

(9) Therefore the present invention also relates to a process (P3), which is process (P), (P1) or (P2), wherein the lipophilic material in the solid formulation is 65-80 wt-%, based on the total weight of the solid formulation.

(10) Lipophilic material in the context of the present invention can be waxes as well as fats.

(11) Waxes in the context of the present invention are organic compounds that characteristically consist of a long alkyl chains. Natural waxes (plant, animal) are typically esters of fatty acids and long chain alcohols. Synthetic waxes are long-chain hydrocarbons lacking functional groups.

(12) Fats, which are used for the embodiments of the present invention, consist of a wide group of compounds that are generally soluble in organic solvents and largely insoluble in water.

(13) Hydrogenated fats (or saturated fats) in the context of the present invention are generally triesters of glycerol and fatty acids. Fatty acids are chains of carbon and hydrogen atoms, with a carboxylic acid group at one end. Such fats can have natural or synthetic origin. It is possible to hydrogenate a (poly)unsaturated fat to obtain a hydrogenated (saturated) fat.

(14) Especially suitable waxes and fats have a drop point of from 30 to 90 C., preferably 40 to 80 C. Waxes in the context of the present invention are organic compounds that characteristically consist of a long alkyl chains. Natural waxes (plant, animal) are typically esters of fatty acids and long chain alcohols. Synthetic waxes are long-chain hydrocarbons lacking functional groups.

(15) The drop point of a material is that temperature (in C.) when the material begins to melt under standardized conditions. The material is heated so long until it changes the state of matter from solid to liquid. The drop point is the temperature when the first drop is released from the material. The determination of the drop point (Tropfpunkt) is carried out as described in the standard norm DIN ISO 2176.

(16) Preferred examples of waxes and fats suitable for the present invention are glycerol monostearate, carnauba wax, candelilla wax, palmitic acid, stearic acid hydrogenated cottonseed oil and hydrogenated rapeseed oil. These compounds can be used as such or as mixtures.

(17) Therefore the present invention also relates to a process (P4), which is process (P), (P1), (P2) or (P3), wherein the lipophilic material are waxes and fats having a drop point of from 30 to 90 C., preferably 40 to 80 C.

(18) Therefore the present invention also relates to a process (P4), which is process (P4), wherein the lipophilic material are waxes and fats chosen from the group consisting of glycerol monostearate, carnauba wax, candelilla wax, palmitic acid, stearic acid hydrogenated cottonseed oil and hydrogenated rapeseed oil. These compounds can be used as such or as mixtures.

(19) Therefore the present invention also relates to a process (P4), which is process (P4) or (P4), wherein the lipophilic material is glycerol monostearate.

(20) It is clear that the lipophilic material, which are not in a liquid state need to be molten before used in the process according to the present invention.

(21) Therefore the present invention also relates to a process (P5), which is process (P), (P1), (P2), (P3), (P4), (P4) or (P4), wherein the lipophilic material, which is solid at room temperature is molten before used in the process.

(22) To melt the lipophilic material usually a temperature of above 30 C. is chosen. The temperature is depending on the melting or drop point of lipophilic material. A usual and also preferred range is between 50 C. and 100 C. (more preferably 60 C. 100 C.).

(23) Therefore the present invention also relates to a process (P5), which is process (P5), wherein the lipophilic material, which is solid at room temperature is heated up to a temperature of above 30 C. before used in the process.

(24) Therefore the present invention also relates to a process (P5), which is process (P5), wherein the lipophilic material, which is solid at room temperature is heated up to a temperature of between 50 C. and 100 C. (more preferably between 60 C. and 100 C.).

(25) Therefore the present invention also relates to a process (P5), which is process (P5), wherein the lipophilic material, which is solid at room temperature is heated up to a temperature of between 60 C. and 100 C.

(26) The average particle sizes (d50) of the particles of the solid formulation obtained by any of the process (P), (P1), (P2), (P3), (P4), (P4), (P4), (P5), (P5), (P5) and/or (P5) is usually between 40-500 m. The average particle sizes (d50) is measured by a MALVERN MasterSizer3000 (for all values of the present patent application).

(27) The therapeutically active or nutritious plant extract is usually and preferably suspended in the liquid lipophilic material under stirring.

(28) In step (b) of the process according to the present invention, the suspension (formed from the least one therapeutically active or nutritious plant extract and the least one lipophilic material) is atomized into a spray tower, wherein the air (inside the spray tower) has such a temperature that the lipophilic material solidifies.

(29) This temperature is usually below 50 C., preferably below 40. (Usually a range of 10 to 50 C., preferably 10 to 40 C.).

(30) Therefore the present invention also relates to a process (P6), which is process (P), (P1), (P2), (P3), (P4), (P4), (P4), (P5), (P5), (P5) or (P5), wherein the suspension is atomized into a spray tower, wherein the air has s temperature of below 50 C.

(31) Therefore the present invention also relates to a process (P6), which is process (P), (P1), (P2), (P3), (P4), (P4), (P4), (P5), (P5), (P5) or (P5), wherein the suspension is atomized into a spray tower, wherein the air has a temperature of below 40 C.

(32) Therefore the present invention also relates to a process (P6), which is process (P), (P1), (P2), (P3), (P4), (P4), (P4), (P5), (P5), (P5) or (P5), wherein the suspension is atomized into a spray tower, wherein the air has a temperature of 10 to 50 C.

(33) Therefore the present invention also relates to a process (P6), which is process (P), (P1), (P2), (P3), (P4), (P4), (P4), (P5), (P5), (P5) or (P5), wherein the suspension is atomized into a spray tower, wherein the air has a temperature of 10 to 40 C.

(34) The solid formulation according to the present invention can also comprise other ingredients, which can be useful for the solid formulation, for the production of the solid formulation and/or the use of the solid formulation.

(35) These other ingredients can be added at any stage to the process according to the present invention. This means they can be added to the therapeutically active or nutritious plant extract and/or to the lipophilic material and/or to the suspension. Optionally also some auxiliary compound can be used in the spray drying process.

(36) Furthermore the present invention relates to a process wherein the solid formulation consists of (i) 20-40, weight-% (wt-%), based on the total weight of the solid formulation, of least one therapeutically active or nutritious plant extract, and (ii) 60-80 wt-%, based on the total weight of the solid formulation, of glycerol monostearate.

(37) Therefore the present invention also relates to a process (P7), which is process (P), (P1), (P2), (P3), (P4), (P4), (P4), (P5), (P5), (P5), (P5), (P6), (P6), (P6) or (P6), wherein the solid formulation consists of (i) 20-40, weight-% (wt-%), based on the total weight of the solid formulation, of least one therapeutically active or nutritious plant extract, and (ii) 60-80 wt-%, based on the total weight of the solid formulation, of glycerol monostearate

(38) A very preferred embodiment is the following process, wherein (a) 20-40, weight-% (wt-%), based on the total weight of the solid formulation, glycerol monostearate is molted at a temperature of between 60 C. and 100 C., and (b) 60-80 wt-%, based on the total weight of the solid formulation, Acerola plant extract is suspended in the molten glycerol monostearate (by stirring), and then afterwards (c) this suspension is atomized into a spray tower, wherein the air (in the spray tower) has a temperature of below 40 C.

(39) Therefore the present invention also relates to a process (P8), wherein (a) 20-40, weight-% (wt-%), based on the total weight of the solid formulation, glycerol monostearate is molted at a temperature of between 60 C. and 100 C., and (b) 60-80 wt-%, based on the total weight of the solid formulation, Acerola plant extract is suspended in the molten glycerol monostearate (by stirring), and then afterwards (c) this suspension is atomized into a spray tower, wherein the air (in the spray tower) has a temperature of below 40 C.

(40) As stated above the solid formulation obtained by the process according to the present invention is in a powder form.

(41) Furthermore the present invention relates to a solid formulation (F1) comprising (i) 20-40, weight-% (wt-%), based on the total weight of the solid formulation, of least one therapeutically active or nutritious plant extract, and (ii) 60-80 wt-%, based on the total weight of the solid formulation, of at least one lipophilic material.

(42) The new and improved solid formulation has also the additional advantages that the solid formulation is easy to produce (conventional spray technology), the solid formulation has excellent properties to mask sour/bitter or adstringent tastes, the solid formulation is a non-sticky powder, and the one therapeutically active or nutritious plant extract is very well protected against moisture.

(43) The therapeutically active or nutritious plant extract is preferably an Acerola plant extract.

(44) Therefore the present invention also relates to a solid formulation (F2), which is formulation (F1), wherein the therapeutically active or nutritious plant extract is an Acerola plant extract.

(45) In a preferred embodiment, the amount of this plant extract is 20-35 wt-%, based on the total weight of the solid formulation.

(46) Therefore the present invention also relates to a solid formulation (F3), which is formulation (F1) or (F2), wherein the amount of the therapeutically active or nutritious plant extract is 20-35 wt-%, based on the total weight of the solid formulation.

(47) In a preferred embodiment, the amount of the lipophilic material is 65-80 wt-%, based on the total weight of the solid formulation.

(48) Therefore the present invention also relates to a solid formulation (F4), which is formulation (F1), (F2) or (F3), wherein the lipophilic material is 65-80 wt-%, based on the total weight of the solid formulation.

(49) Therefore the present invention also relates to a solid formulation (F5), which is formulation (F1), (F2), (F3) or (F4), wherein the lipophilic material are waxes and fats having a drop point from 30 to 90 C., preferably 40 to 80 C.

(50) Therefore the present invention also relates to a solid formulation (F5), which is formulation (F5), wherein the lipophilic material are waxes and fats chosen from the group consisting of glycerol monostearate, carnauba wax, candelilla wax, palmitic acid, stearic acid hydrogenated cottonseed oil and hydrogenated rapeseed oil. These compounds can be used as such or as mixtures.

(51) Therefore the present invention relates to a solid formulation (F5), which is formulation (F5) or (F5), wherein the lipophilic material is glycerol monostearate.

(52) Therefore the present invention also relates to a solid formulation (F6), which is formulation (F1), (F2), (F3), (F4) or (F5), wherein the average particle sizes (d50) of the particles of the solid formulation according to the present invention is between 40-500 m.

(53) Therefore the present invention also relates to a solid formulation (F7), which consists of (i) 20-40, weight-% (wt-%), based on the total weight of the solid formulation, of least one therapeutically active or nutritious plant extract, and (ii) 60-80 wt-%, based on the total weight of the solid formulation, of glycerol monostearate.

(54) Therefore the present invention also relates to a solid formulation (F7), which consists of (i) 20-40, weight-% (wt-%), based on the total weight of the solid formulation, of an Acerola plant extract, and (ii) 60-80 wt-%, based on the total weight of the solid formulation, of glycerol monostearate.

(55) The solid formulations (F1), (F2), (F3), (F4), (F5), (F6), (F6), (F6), (F7) and (F8) according to the present invention can be used as such or it can be used in any other compositions.

(56) The solid formulations (F1), (F2), (F3), (F4), (F5), (F6), (F6), (F6), (F7) and (F8) as such or preferably the formulations (F1), (F2), (F3), (F4), (F5), (F6), (F6), (F6), (F7) and (F8) incorporated into another composition can be used as food, feed, nutritional supplement and/or personal care products.

(57) Preferred is the use of at least one solid formulation (F1), (F2), (F3), (F4), (F5), (F6), (F6), (F6), (F7) and (F8) in the production of food and/or feed compositions.

(58) The amount of the solid formulation (F1), (F2), (F3), (F4), (F5), (F6), (F6), (F6), (F7) and/or (F8), in the final consumer product, depends on the application and the consumer demand.

(59) Furthermore the present invention relates to food, feed, nutritional supplement and/or personal care products comprising at least one solid formulation (F1), (F2), (F3), (F4), (F5), (F6), (F6), (F6), (F7) and (F8).

(60) These products can be in any commonly known and used form.

(61) The following examples serve to illustrate the invention.

EXAMPLES

Example 1: Acerola 33%

(62) Melt 16.00 kg Glycerol Monostearate in a stirred vessel at 65-85 C.

(63) Suspend 8.00 kg Acerola Powder 20% Vitamin C into the molten Glycerol Monostearate by normal stirring until a homogeneous suspension is made (app. 20-40 min). Maintain 65-85 C. product temperature.

(64) Feed the suspension to a spray tower were an atomizer will generate droplets of a suitable size out of the suspension. The spray tower has to be operated at an air temperatures of 25 C. to solidify the atomized droplets of the suspension.

(65) Collect the solidified product (powder).